Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
COMPLETED
NCT02037126
PHASE2

Psilocybin-facilitated Treatment for Cocaine Use

Sponsor: University of Alabama at Birmingham

View on ClinicalTrials.gov

Summary

The primary purpose of this study is to evaluate the feasibility and estimate the efficacy of psilocybin-facilitated treatment for cocaine use. We also will monitor the impact of psilocybin-facilitated treatment on the use of other drugs and outcomes relevant to cocaine involvement. MRI assessment is a unique aspect of this study. As a potential biological mechanism of psilocybin's effect includes changes in default mode network functional connectivity (Carhart-Harris et al., 2012), we will determine if psilocybin's therapeutic effects are mediated by such changes. Moreover, as Glx (a brain metabolite that reflects glutamate) abnormalities have been shown to play a role in cocaine addiction, we will determine if psilocybin impacts Glx in the anterior cingulate cortex and hippocampus.

Key Details

Gender

All

Age Range

25 Years - Any

Study Type

INTERVENTIONAL

Enrollment

40

Start Date

2015-05

Completion Date

2024-05

Last Updated

2026-05-18

Healthy Volunteers

No

Interventions

DRUG

Psilocybin

this has been used in treating obsessive-compulsive disorders, cluster headaches, anxiety, and drug dependence.

DRUG

Diphenhydramine

This drug will be used as the control. Diphenhydramine is a histamine blocker.

Locations (1)

UAB Outpatient Clinical Research Unit

Birmingham, Alabama, United States